Figure 2

Photographs of the left eye 20 months (at the time of PIC recurrence, A-D) and 23 months (E) after the initial visit. A, The size of a punctate subretinal yellowish-white lesion (arrow) at the nasal side of the fovea OS had enlarged since the last visit (Figure 1A, F), although the number of PIC lesions remained unchanged. B, C, An area of hyperfluorescence on late-phase FA (B, arrow) or hypofluorescence on initial-phase ICGA (C, arrow) corresponding to the recurrent PIC lesion had expanded since the initial visit (Figure 1B, C). D, A cross-sectional enhanced-depth imaging (EDI)-OCT image taken at the same site depicted in Figure 1E showed the development of a hump-shaped hyperreflective chorioretinal nodule corresponding to the recurrent PIC lesion (arrowhead), with surrounding IS/OS loss (arrows). Choroidal thickness beneath the lesion was 164.0 μm. E, Three months after the resumption of systemic prednisolone therapy, the size of the hyperreflective lesion on EDI-OCT remained unchanged with slightly increased hyperreflectivity within the lesion (arrowhead) and improved IS/OS integrity. Choroidal thickness at the lesion site decreased to 122.7 μm.